Share Price and Basic Stock Data

Last Updated: November 14, 2024, 3:28 pm

Market Cap	1,04,173 Cr.
Current Price	2,599
High / Low	2,883/1,820
Stock P/E	52.0
Book Value	269
Dividend Yield	0.00 %
ROCE	24.6 %
ROE	19.7 %
Face Value	1.00
PEG Ratio	4.26

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Mankind Pharma Ltd

Competitors of Mankind Pharma Ltd

Stock Name	Market Cap	Current Price	High / Low	Stock P/E	Book Value	Dividend Yield	ROCE	ROE	Face Value
Mankind Pharma Ltd	1,04,173 Cr.	2,599	2,883/1,820	52.0	269	0.00 %	24.6 %	19.7 %	1.00
Industry Average	104,173.00 Cr	2,599.00		52.00	269.00	0.00%	24.60%	19.70%	1.00

All Competitor Stocks of Mankind Pharma Ltd

Quarterly Result

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Sales	1,645	2,061	2,258	1,936	1,872	2,092	2,260	2,359	1,997	2,403	2,530
Expenses	1,336	1,641	1,735	1,563	1,491	1,594	1,662	1,755	1,481	1,831	1,778
Operating Profit	309	420	522	374	381	498	598	603	515	572	752
OPM %	19%	20%	23%	19%	20%	24%	26%	26%	26%	24%	30%
Other Income	8	19	69	32	42	87	84	67	107	124	138
Interest	11	9	8	9	1	2	4	4	4	6	2
Depreciation	36	65	66	71	67	69	77	90	82	83	85
Profit before tax	270	365	517	326	355	514	601	576	536	607	802
Tax %	20%	18%	19%	24%	21%	20%	21%	15%	15%	15%	21%
Net Profit	217	298	420	249	281	409	473	487	454	513	634
EPS in Rs	5.43	7.44	10.49	6.21	7.01	10.22	11.80	12.16	11.34	12.82	15.84

Last Updated: November 6, 2024, 7:11 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	3,918	3,829	4,794	5,523	7,486	8,127	9,265	9,212
Expenses	3,141	3,124	3,550	4,151	5,644	6,429	6,939	6,886
Operating Profit	778	705	1,244	1,372	1,842	1,698	2,326	2,326
OPM %	20%	18%	26%	25%	25%	21%	25%	25%
Other Income	209	64	94	154	200	163	267	357
Interest	18	40	11	8	48	28	15	19
Depreciation	28	38	62	78	123	270	318	332
Profit before tax	941	691	1,265	1,440	1,871	1,563	2,260	2,331
Tax %	26%	26%	24%	25%	26%	20%	19%
Net Profit	694	514	958	1,084	1,389	1,248	1,823	1,928
EPS in Rs	17.33	12.83	23.92	27.07	34.68	31.16	45.52	48.12
Dividend Payout %	0%	0%	32%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	-25.94%	86.38%	13.15%	28.14%	-10.15%	46.07%
Change in YoY Net Profit Growth (%)	0.00%	112.32%	-73.23%	14.98%	-38.29%	56.22%

Mankind Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2018-2019 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	%
5 Years:	19%
3 Years:	19%
TTM:	14%

Compounded Profit Growth
10 Years:	%
5 Years:	27%
3 Years:	18%
TTM:	48%

Stock Price CAGR
10 Years:	%
5 Years:	%
3 Years:	%
1 Year:	39%

Return on Equity
10 Years:	%
5 Years:	22%
3 Years:	20%
Last Year:	20%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 5:42 pm

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	40	40	40	40	40	40	40	40
Reserves	2,957	3,025	3,611	4,694	6,500	7,744	9,584	10,747
Borrowings	360	190	3	101	688	5	9	207
Other Liabilities	652	596	877	1,045	1,710	1,583	1,785	2,265
Total Liabilities	4,009	3,851	4,531	5,880	8,939	9,371	11,418	13,260
Fixed Assets	534	778	945	987	2,927	3,142	3,404	3,427
CWIP	322	211	148	166	387	495	188	121
Investments	1,402	1,698	1,784	2,397	2,526	3,102	4,430	5,805
Other Assets	1,751	1,164	1,655	2,330	3,100	2,632	3,396	3,907
Total Assets	4,009	3,851	4,531	5,880	8,939	9,371	11,418	13,260

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	540	537	960	983	821	1,799	1,983
Cash from Investing Activity +	-516	-306	-396	-1,127	-1,360	-1,041	-1,919
Cash from Financing Activity +	8	-240	-559	89	579	-710	-9
Net Cash Flow	31	-9	5	-55	40	48	55

Free Cash Flow

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	418.00	515.00	-2.00	-100.00	-687.00	-4.00	-7.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	23	13	32	24	23	22	30
Inventory Days	120	126	124	169	183	132	135
Days Payable	115	101	113	122	133	103	107
Cash Conversion Cycle	27	38	43	72	73	52	58
Working Capital Days	95	44	41	49	60	40	35
ROCE %		22%	36%	33%	30%	21%	25%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Promoters	76.50%	76.50%	76.50%	74.88%	74.87%
FIIs	4.18%	4.18%	6.74%	9.87%	11.58%
DIIs	4.65%	4.56%	9.78%	11.14%	9.94%
Public	14.67%	14.76%	6.97%	4.10%	3.61%
No. of Shareholders	1,31,918	1,34,731	1,27,449	1,35,116	1,53,450

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
SBI Blue Chip Fund	2,807,055	1.38	599.47	845,530	2024-11-14	231.99%
Axis ELSS Tax Saver Fund	1,961,633	1.23	418.93	845,530	2024-11-14	132%
Axis Bluechip Fund	1,212,614	0.79	258.97	845,530	2024-11-14	43.41%
ICICI Prudential Balanced Advantage Fund	1,154,141	0.45	246.48	845,530	2024-11-14	36.5%
SBI Magnum Midcap Fund	1,123,909	1.46	240.02	845,530	2024-11-14	32.92%
HDFC Top 100 Fund - Regular Plan	1,044,572	0.7	223.08	845,530	2024-11-14	23.54%
Nippon India Pharma Fund	900,794	2.7	192.37	845,530	2024-11-14	6.54%
ICICI Prudential Focused Equity Fund	845,691	2.5	180.61	845,530	2024-11-14	0.02%
ICICI Prudential Value Discovery Fund	845,530	0.44	180.57	845,530	2024-11-14	0%
ICICI Prudential Equity & Debt Fund	800,648	0.53	170.99	845,530	2024-11-14	-5.31%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	1.00	1.00	1.00	1.00	1.00
Basic EPS (Rs.)	47.75	32.00	35.78	31.59	25.72
Diluted EPS (Rs.)	47.68	32.00	35.78	31.59	25.72
Cash EPS (Rs.)	58.03	40.52	40.07	34.96	28.55
Book Value[Excl.RevalReserv]/Share (Rs.)	239.04	190.30	157.68	121.39	91.65
Book Value[Incl.RevalReserv]/Share (Rs.)	239.04	190.30	157.68	121.39	91.65
Revenue From Operations / Share (Rs.)	257.99	218.41	194.25	155.13	146.41
PBDIT / Share (Rs.)	70.29	50.66	54.55	45.41	38.62
PBIT / Share (Rs.)	60.35	42.52	50.39	42.44	36.15
PBT / Share (Rs.)	59.52	41.41	48.93	41.94	35.60
Net Profit / Share (Rs.)	48.09	32.38	35.91	31.99	26.08
NP After MI And SOA / Share (Rs.)	47.75	32.00	35.78	31.59	25.72
PBDIT Margin (%)	27.24	23.19	28.08	29.27	26.37
PBIT Margin (%)	23.39	19.46	25.94	27.35	24.69
PBT Margin (%)	23.06	18.95	25.18	27.03	24.31
Net Profit Margin (%)	18.64	14.82	18.48	20.61	17.81
NP After MI And SOA Margin (%)	18.50	14.65	18.42	20.36	17.56
Return on Networth / Equity (%)	20.43	17.24	23.28	26.79	29.56
Return on Capital Employeed (%)	24.56	21.69	30.94	33.87	37.96
Return On Assets (%)	15.98	13.19	15.67	19.85	20.31
Long Term Debt / Equity (X)	0.00	0.00	0.01	0.01	0.01
Total Debt / Equity (X)	0.02	0.02	0.14	0.05	0.03
Asset Turnover Ratio (%)	0.95	0.87	0.98	1.01	0.00
Current Ratio (X)	3.14	2.32	1.68	2.89	2.24
Quick Ratio (X)	2.40	1.52	1.01	2.01	1.53
Inventory Turnover Ratio (X)	1.21	0.50	0.64	0.57	0.00
Dividend Payout Ratio (NP) (%)	0.00	0.00	0.00	0.00	29.35
Dividend Payout Ratio (CP) (%)	0.00	0.00	0.00	0.00	26.77
Earning Retention Ratio (%)	0.00	0.00	0.00	0.00	70.65
Cash Earning Retention Ratio (%)	0.00	0.00	0.00	0.00	73.23
Interest Coverage Ratio (X)	83.98	45.63	37.29	90.29	70.42
Interest Coverage Ratio (Post Tax) (X)	58.45	30.17	25.54	64.60	48.54
Enterprise Value (Cr.)	91250.99	0.00	0.00	0.00	0.00
EV / Net Operating Revenue (X)	8.83	0.00	0.00	0.00	0.00
EV / EBITDA (X)	32.41	0.00	0.00	0.00	0.00
MarketCap / Net Operating Revenue (X)	8.90	0.00	0.00	0.00	0.00
Retention Ratios (%)	0.00	0.00	0.00	0.00	70.64
Price / BV (X)	9.83	0.00	0.00	0.00	0.00
Price / Net Operating Revenue (X)	8.90	0.00	0.00	0.00	0.00
EarningsYield	0.02	0.00	0.00	0.00	0.00

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Mankind Pharma Ltd as of November 15, 2024 is: 2,810.75

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 15, 2024, Mankind Pharma Ltd is Undervalued by 8.15% compared to the current share price 2,599.00

Intrinsic Value of Mankind Pharma Ltd as of November 15, 2024 is: 3,153.48

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 15, 2024, Mankind Pharma Ltd is Undervalued by 21.33% compared to the current share price 2,599.00

Last 5 Year EPS CAGR: 12.19%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 23.86%, which is a positive sign. The company has higher reserves (6,107.75 cr) compared to borrowings (195.38 cr), indicating strong financial stability. The company has shown consistent growth in sales (6.00 cr) and profit (205.00 cr) over the years.	The stock has a high average Working Capital Days of 52.00, which may not be favorable. The stock has a high average Cash Conversion Cycle of 51.86, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Mankind Pharma Ltd:
1. Net Profit Margin: 18.64%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 24.56% (Industry Average ROCE: 24.6%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 20.43% (Industry Average ROE: 19.7%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 58.45
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 2.4
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 52 (Industry average Stock P/E: 52)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.02
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Pharmaceuticals

INDUSTRY	ADDRESS	CONTACT
208, Okhla Industrial Estate, New Delhi Delhi 110020	Mr.	Ramesh%20Juneja Chairman%20&%20Wholetime%20Director

Management
Name	Position Held
Mr. Rajeev Juneja	Vice Chairman & Mng.Director
Ms. Sheetal Arora	WholeTime Director & CEO
Mr. Satish Kumar Sharma	Whole Time Director
Mr. Vivek Kalra	Independent Director
Mr. Tilokchand Punamchand Ostwal	Independent Director
Mr. Surendra Lunia	Independent Director
Mr. Bharat Anand	Independent Director
Mr. Vijaya Sampath	Independent Director

FAQ

What is the latest intrinsic value of Mankind Pharma Ltd?

The latest intrinsic value of Mankind Pharma Ltd as on 15 November 2024 is ₹2810.75, which is 8.15% higher than the current market price of ₹2,599.00.

What is the Market Cap of Mankind Pharma Ltd?

The Market Cap of Mankind Pharma Ltd is 1,04,173 Cr..

What is the current Stock Price of Mankind Pharma Ltd as on 15 November 2024?

The current stock price of Mankind Pharma Ltd as on 15 November 2024 is ₹2,599.

What is the High / Low of Mankind Pharma Ltd stocks in FY 2024?

In FY 2024, the High / Low of Mankind Pharma Ltd stocks is 2,883/1,820.

What is the Stock P/E of Mankind Pharma Ltd?

The Stock P/E of Mankind Pharma Ltd is 52.0.

What is the Book Value of Mankind Pharma Ltd?

The Book Value of Mankind Pharma Ltd is 269.

What is the Dividend Yield of Mankind Pharma Ltd?

The Dividend Yield of Mankind Pharma Ltd is 0.00 %.

What is the ROCE of Mankind Pharma Ltd?

The ROCE of Mankind Pharma Ltd is 24.6 %.

What is the ROE of Mankind Pharma Ltd?

The ROE of Mankind Pharma Ltd is 19.7 %.

What is the Face Value of Mankind Pharma Ltd?

The Face Value of Mankind Pharma Ltd is 1.00.